Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONTRESCC: Neoadjuvant Pembrolizumab in ESCC
NCT06907602Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking Union Medical College Hospital. Started Jan 2024; status: recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06907602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907602.